Brain Clearance Architecture: Drug Targets
These speculations extend the Chayama et al. (2026) (Chayama et al. 2026) brain clearance architecture into investigational and repurposed drug targets. Doses are from non-ME/CFS populations unless stated. All are research hypotheses, not clinical recommendations.
For patients: do not act on this chapter — every entry is a research hypothesis explicitly “not a clinical recommendation”, with doses from non-ME/CFS populations.
For caregivers: no direct use; the drug targets are investigational and unsuitable for home application.
For clinicians: read only to understand which investigational or repurposed drugs target the glymphatic pump, perivascular structure, and AQP4 — none are established ME/CFS treatments.
For researchers: the primary audience — each speculation proposes a drug target on the Chayama brain-clearance architecture with a mechanism, dose source, and certainty rating for hypothesis testing.
1 Glymphatic Pump Enhancement
Certainty: 0.35. (0.40→0.35: Sulheim 2014 clonidine RCT null in adolescent CFS (Sulheim et al. 2014) provides negative evidence for the broader mechanism — if clonidine improved glymphatic clearance via NE oscillation stabilisation, some clinical benefit should have been detectable. The central NE deficiency documented in ME/CFS (Aregawi et al. 2026) means clonidine would further suppress already-low LC output, potentially worsening glymphatic clearance rather than improving it. The distinction between suppressing “excessive tonic NE” (the prior rationale) and “already-low tonic NE” is critical and was not accounted for.) NE oscillations at approximately 0.05 Hz drive vasomotion and the fast advective component of glymphatic clearance (Hauglund 2025). Chayama et al. show that NE-driven vasomotion powers clearance through dura and skull compartments (Chayama et al. 2026). Low-dose clonidine (0.025–0.05 mg at bedtime) was proposed to reduce excessive tonic NE drive while preserving LC oscillatory competence, but the Aregawi et al. (2026) demonstration of low central NE in ME/CFS undermines this rationale: there is no excessive tonic drive to reduce. The Sulheim et al. (2014) RCT of clonidine in adolescent CFS (n=120) found no symptom improvement, consistent with the mismatch model in which central NE is pathologically low (Sulheim et al. 2014). Nevertheless, the concept (restoring infraslow vasomotion rhythm) remains mechanistically sound; the question is whether other interventions (DORAs, atomoxetine timed to circadian phase) could achieve this without suppressing LC output.
- Falsifiable: ME/CFS patients with advective-dominant impairment (fast flow less than 50 percent of control on MR-AIV) will show improved fast advective flow (greater than 25 percent increase) after 4 weeks of low-dose clonidine, with corresponding brain fog improvement. Falsified if clonidine suppresses both fast and slow flow or worsens DTI-ALPS.
- Limitations: No direct glymphatic data for clonidine exist in any species. Hypotension risk in POTS patients.
Certainty: 0.30. AQP4 provides the osmotic gradient driving the slow diffusive component of glymphatic transport (Toscano 2026, approximately 0.1 micron/s). In ME/CFS, AQP4 is depolarized at astrocytic endfeet. TGN-020 is an investigational AQP4 modulator that could restore polarized AQP4 localization to the perivascular endfoot membrane, enhancing slow diffusion. Chayama et al. (Chayama et al. 2026) confirm that AQP4-rich perivascular spaces are the physiological clearance conduits.
- Falsifiable: ME/CFS patients with diffusive-dominant impairment (fast flow greater than 70 percent of control, slow flow less than 50 percent of control on MR-AIV) will show slow diffusion improvement greater than 30 percent within 4 weeks of TGN-020.
- Limitations: TGN-020 is investigational only; no human ME/CFS data. AQP4 inhibition may impair water homeostasis elsewhere (kidney, retina).
2 Inflammation-Induced Routing Protection
Certainty: 0.35. Chayama et al. (Chayama et al. 2026) demonstrated that acute inflammation (LPS, a TLR4 agonist) shunts brain-derived proteins into the bloodstream, bypassing tolerogenic border clearance routes. PEM in ME/CFS involves a cytokine surge (IL-1beta, IL-6, TNF-alpha). A TLR4 antagonist could block the signaling cascade that triggers routing disruption during exertion, preventing neuronal protein leakage into blood.
- Falsifiable: ME/CFS patients pretreated with TAK-242 before standardized exertion will show attenuated plasma CNS protein rise (NfL less than 1.3x baseline) compared to placebo (NfL greater than 2.5x baseline), with corresponding reduced PEM severity.
- Limitations: TAK-242 is investigational. LPS model is acute endotoxemia; PEM cytokine elevations are orders of magnitude lower. TLR4 blockade may impair innate immune defense against infection.
3 Perivascular Structure Restoration
Certainty: 0.40. Chayama et al. (Chayama et al. 2026) document perivascular spaces as the primary clearance conduits. Chronic glymphatic impairment in ME/CFS involves perivascular fibrosis and basement membrane thickening (Section Glymphatic Dysfunction and Brain Waste Accumulation, approximately 70x recovery timescale). Losartan, an angiotensin II receptor blocker, has anti-fibrotic properties independent of its antihypertensive effects — documented in kidney, liver, and cardiac fibrosis models.
- Falsifiable: ME/CFS patients with documented perivascular fibrosis (over 5 years disease duration) will show improved perivascular compliance on MR-AIV after 6 months of losartan (25–50 mg/day), with corresponding DTI-ALPS improvement.
- Limitations: Anti-fibrotic effects documented in non-CNS tissues only. Hypotension risk in ME/CFS POTS patients. No CNS perivascular fibrosis reversal data exist.
Certainty: 0.30. Chayama et al. (Chayama et al. 2026) show that glial-vascular interfaces are critical for clearance. Chronic neuroinflammation drives astrocyte reactivity, endfoot retraction, and GFAP upregulation. Minocycline, a tetracycline antibiotic with anti-inflammatory and microglial-modulating properties, reduces reactive astrogliosis in multiple CNS injury models. By dampening microglial activation and allowing astrocytic endfoot re-extension, minocycline could restore the perivascular contact surface area needed for AQP4-mediated clearance.
- Falsifiable: ME/CFS patients on minocycline (100 mg BID) for 12 weeks will show reduced GFAP levels (plasma or CSF) and improved estimated AQP4-mediated permeability on MR-AIV.
- Limitations: Minocycline has documented CNS anti-inflammatory effects but no ME/CFS glymphatic data. Long-term antibiotic use risks: dysbiosis, photosensitivity, vestibular toxicity.
Certainty: 0.32. Glycine is a simple amino acid with documented anti-fibrotic properties in liver and kidney via inhibition of TGF-beta signaling and collagen synthesis. Chayama et al. (Chayama et al. 2026) demonstrate that perivascular spaces are the structural conduits requiring patency. Glycine could reduce perivascular collagen deposition and support clearance route integrity.
- Falsifiable: ME/CFS patients on glycine (3–5 g/day, divided doses) for 12 weeks will show improved perivascular compliance on MR-AIV and reduced CSF collagen breakdown products.
- Limitations: CNS anti-fibrotic effects untested. Glycine is a co-agonist at NMDA receptors — theoretical concern about excitotoxicity at high doses, not observed clinically at these doses.
4 AQP4 and Oxidative Protection
Certainty: 0.35. AQP4 is susceptible to oxidative damage, which contributes to depolarization at astrocytic endfeet. Systemic oxidative stress is documented in ME/CFS (reduced cortical glutathione, Section Oxidative and Nitrosative Stress as Symptom Amplifier). Alpha-lipoic acid is a potent antioxidant that crosses the BBB. By reducing AQP4 oxidation, ALA may preserve AQP4 polarization and slow diffusive glymphatic transport. Chayama et al. (Chayama et al. 2026) confirm AQP4-rich perivascular spaces are the clearance conduits.
- Falsifiable: ME/CFS patients on ALA (600 mg daily) for 8 weeks will show preserved AQP4-mediated transport (estimated from MR-AIV permeability) compared to decline in placebo, with corresponding DTI-ALPS stabilization.
- Limitations: AQP4 oxidation in ME/CFS is not directly measured. DTI-ALPS is an indirect proxy.
Certainty: 0.30. Taurine is an organic osmolyte concentrated in astrocytes that maintains cell volume and osmotic gradients. By supporting the osmotic driving force for AQP4-mediated water transport, taurine could enhance the slow diffusive component of glymphatic flow. Chayama et al. (Chayama et al. 2026) show that perivascular AQP4-rich interfaces are the clearance conduits.
- Falsifiable: ME/CFS patients on taurine (2 g/day) for 8 weeks will show improved slow diffusion estimates on MR-AIV and reduced brain fog severity relative to placebo.
- Limitations: Osmotic gradient mechanism is inferred; no direct taurine-glymphatic data exist. Taurine is very safe but mechanism is extrapolated.
Certainty: 0.33. Omega-3 fatty acids (EPA/DHA) incorporate into cell membranes of endothelial cells and astrocytes, increasing membrane fluidity. More fluid perivascular membranes may enhance CSF-ISF exchange efficiency and reduce flow resistance. Chayama et al. (Chayama et al. 2026) demonstrate that perivascular interfaces are the physiological clearance conduits.
- Falsifiable: ME/CFS patients on EPA/DHA (3 g/day) for 12 weeks will show improved perivascular compliance on MR-AIV and reduced brain fog severity relative to placebo.
- Limitations: Membrane fluidity-glymphatic link is theoretical. DHA/EPA dosing and ratio for CNS effects not established in ME/CFS.
Certainty: 0.38. NAC is a glutathione precursor that crosses the BBB. One pilot trial in ME/CFS normalized cortical glutathione, ventricular lactate, and symptom scores (Shungu 2016). By reducing perivascular oxidative stress, NAC may preserve AQP4 polarization at astrocytic endfeet. Chayama et al. (Chayama et al. 2026) confirm AQP4-rich perivascular spaces are the clearance conduits.
- Falsifiable: ME/CFS patients on NAC (1200 mg BID) for 8 weeks will show improved AQP4-mediated transport estimates on MR-AIV compared to placebo, with corresponding DTI-ALPS improvement.
- Limitations: AQP4 polarization in ME/CFS not directly measured. Single pilot trial; replication pending.